Alteogen said on the 17th that it received European Commission (EC) approval for the item "ILUXV," an Eylea biosimilar (biologic drug copy). Eylea is an ophthalmic disease treatment, and its sales reached 13 trillion won last year.
Alteogen subsidiary Alteogen Biologics conducted a phase 3 clinical trial from 2022 to 2024 on 431 patients with wet age-related macular degeneration in 12 countries, including Europe, Korea, and Japan. The company said ILUXV demonstrated equivalent efficacy and safety to Eylea.
Park Sun-jae, Alteogen CEO, said, "We will improve product access for patients suffering from ophthalmic diseases."
※ This article has been translated by AI. Share your feedback here.